

Respiratory Viruses Surveillance Bulletin

Epidemiological Week 47
(Up to 23 November 2025)



Please provide your feedback or suggestions through the [link](#) or QR code:



Contents

Regional situation at a glance	1
Updates from countries and areas by WHO transmission zones	3
Influenza and SARS-CoV-2 activity in the Eastern Asia transmission zone	3
Influenza and SARS-CoV-2 activity in the South East Asia transmission zone	5
Influenza and SARS-CoV-2 activity in the Oceania Melanesia and Polynesia	7
Influenza like illness (ILI) situation in the Pacific Island countries and areas (PICs).....	9
Tracking SARS-CoV-2 variants in the Western Pacific Region	11
Data Sources and Disclaimer	12

Regional situation at a glance*

- Influenza positivity has continued to sharply increase in the region and reached 35% in week 47 (Figure 1).
- SARS-CoV-2 positivity continues to decline with a slight upsurge reported in the last week, which may be related to incomplete reporting (Figure 1).
- The predominant circulating influenza subtype remains influenza A(H3N2) (Figure 2).
- Since the last surveillance bulletin, several media articles¹ from across the region describe an earlier-than-usual rise in influenza activity this season, with several outlets noting a sharper increase compared with the same period last year. Measures recommended include vaccination, seeking early treatment, personal hygiene measures and school closures.

*As data submission for the most recent week has not been received from all countries the current trends should be interpreted with caution.

¹ [Glbai Times](#); [nippon.com](#); [JoongAng Daily](#); [Parents need to know: Signs of severe influenza A in children](#)




Figure 1: Number of sentinel surveillance specimens tested for Influenza and SARS-CoV-2 and positivity rates as reported to RespiMart from countries and areas of the Western Pacific Region, from 25 November 2024 to 23 November 2025 (Source: [GISRS surveillance data reported to RespiMart](#))

Note: Sentinel surveillance specimens are not tested for SARS-CoV-2 in China, Brunei Darussalam, Malaysia and Fiji. As data submission may not be completed for the most recent week, current trends should be interpreted with caution.




Figure 2. Influenza virus detections by subtype in the Western Pacific Region, 25 November 2024 to 23 November 2025 (Source: [Influenza Laboratory Surveillance Information](#))

Updates from countries and areas by WHO transmission zones

The figures below illustrate sentinel surveillance data submitted to RespiMart from countries and areas in the Western Pacific Region. Countries and areas are grouped by transmission zone². Typically, all sentinel surveillance specimens are tested for influenza and SARS-CoV-2. However, in selected countries (China, Brunei Darussalam and Malaysia) sentinel surveillance specimens are only tested for influenza. Additionally, Pacific Island Countries are currently only reporting syndromic influenza like illness (ILI) data as virological testing has not been initiated.

For each country and area in a WHO transmission zone, data are presented for the number of specimens tested and percent positivity for influenza and/or SARS-CoV-2, and the circulating influenza subtypes. Each figure illustrates trends based on a rolling 52-week timeframe. The vertical axis scale differs by country to reflect the weekly number of samples tested and to optimize the clarity of the charts.

Influenza and SARS-CoV-2 activity in the Eastern Asia transmission zone




Figure 3: Number of specimens processed and % of specimens positive for influenza and SARS-CoV-2 by week, 25 November 2024 to 23 November 2025

² [Influenza transmission zones](#)

* China does not test sentinel specimens for SARS-CoV-2. Data for China and China Hong Kong SAR, are presented separately.

** Denominator data are available for Japan since week 15, 2025.

Influenza activity is increasing in all countries in the Eastern Asia transmission zone (Figure 3), with the exception of China, Hong Kong SAR and Japan where a decrease was observed in the recent week. In this transmission zone, influenza positivity ranged from around 6% (China, Hong Kong SAR) to 47% (Mongolia) in the most recent week. SARS-CoV-2 positivity has been declining in the Republic of Korea and increasing in Japan in the recent week. The predominant circulating influenza subtype, consistent with the global picture, is influenza A(H3) in this transmission zone (Figure 4).




Figure 4: Influenza virus detections by subtype by week, 25 November 2024 to 23 November 2025

* Data for China and China Hong Kong SAR, are presented separately.

** Denominator data are available for Japan since week 15, 2025.

Influenza and SARS-CoV-2 activity in the South-East Asia transmission zone

Influenza activity is mixed in the South-East Asia transmission zone. Positivity decreased in Indonesia, Lao PDR, Singapore, Malaysia and Viet Nam in the past week (Figure 5). Influenza positivity ranged from around 14% (Malaysia) to 58% (Viet Nam) in the most recent week. SARS-CoV-2 positivity remains low and stable in this transmission zone (Figure 5). The predominant circulating subtype is influenza A(H3) in this transmission zone although some countries including Cambodia and Lao PDR continue to detect influenza B(Victoria) (Figure 6).




Figure 5: Number of specimens processed and % of specimens positive for influenza by week, 25 November 2024 to 23 November 2025

* Brunei Darussalam only tests sentinel specimens for influenza.

** Malaysia only tests sentinel specimens for influenza.



Figure 6: Influenza virus detections by subtype by week, 25 November 2024 to 23 November 2025

Influenza and SARS-CoV-2 activity in the Oceania, Melanesia and Polynesia

Influenza activity has declined in Australia since August as expected, while activity in New Zealand remains high (32% positivity in the most recent week) for this time of the year. In Fiji, influenza activity has rapidly increased over the past four weeks with 64% positivity reported in the past week (as of 9 November) (Figure 7). This pattern is unusual for this time of year, as Fiji's influenza season typically aligns with the Southern Hemisphere and the winter peak occurs between June to August. The predominant circulating influenza subtype is influenza A(H3) in this transmission zone (Figure 8).



Figure 7: Number of specimens processed and % of specimens positive for influenza and SARS-CoV-2 by week, 25 November 2024 to 23 November 2025

* Fiji only tests sentinel specimens for influenza.




Figure 8: Influenza virus detections by subtype by week, 25 November 2024 to 23 November 2025

Influenza like illness (ILI) situation in the Pacific Island countries and areas (PICs)

The Pacific Island countries and areas (PICs) collect data weekly for ILI and SARI through the Pacific Syndromic Surveillance System (PSSS) and report weekly ILI data to RespiMart. Data up to week 46 has been received from PSSS and is presented below. In week 46, 13 of the 21 PICs reported ILI surveillance data to RespiMart (Figure 9). No data are available from American Samoa and Pitcairn Islands has reported zero cases in the last year. An increase in the ILI trend was observed in Federated States of Micronesia, and Vanuatu during this reporting period.






Figure 9: Reported cases of influenza-like illness from week 46, 2024 to week 46, 2025 (Source: Pacific Syndromic Surveillance System Weekly Bulletin)

Tracking SARS-CoV-2 variants in the Western Pacific Region

As of 2 December 2025, relative frequency of circulating SARS-CoV-2 variants in the Western Pacific Region, based on sequences submitted to GISAID by 7 countries (Table 1), is as follows: NB.1.8.1 at 35.2%, B.1.1.529 at 12.3% and KP.3.1.1 at 17.3%, (Figure 10). All circulating variants are derived from Omicron. Contribution of SARS-CoV-2 sequences to GISAID for regional analysis are indicated in Table 1.




Figure 10: Relative frequency (%) of circulating variants in the Western Pacific Region, 2024-2025

Note: Indonesia data is not included in this figure. (Source: [GISAID hCoV-19 Variants Dashboard](#))

Table 1: Number of SARS-CoV-2 sequences submitted to GISAID from the Western Pacific Region*

Country and area	Total number of sequences submitted in quarter 3, 2025	Total number of sequences submitted in quarter 4, 2025	Last submission
American Samoa	0	0	Jan-25
Australia	2 370	661	Nov-25
Brunei Darussalam	11	0	Sep-25
Cambodia	18	0	Sep-25
China	1 661	52	Oct-25
China, Hong Kong SAR	153	56	Nov-25
Guam	26	0	Aug-25
Indonesia	16	0	Aug-25
Japan	1 256	147	Nov-25
Lao PDR	21	0	Aug-25
Malaysia	197	0	Sep-25
Marshall Islands	0	0	Dec-23
Micronesia (Federation of)	1	0	Jul-25
Mongolia	3	2	Oct-25
New Caledonia	6	0	Sep-25
New Zealand	852	124	Nov-25
Northern Mariana Islands	0	0	Mar-24
Palau	0	0	Jun-25
Papua New Guinea	0	0	Dec-22
Philippines	2	0	Jul-25
Republic of Korea	1 843	212	Nov-25
Singapore	1 006	105	Nov-25
Solomon Islands	0	0	Nov-22
Tonga	0	0	Feb-23
Viet Nam	0	0	Jun-25

* All data presented are from: [GISAID SARS-COV-2 variants dashboard](#) (as of 2 December 2025)

Data Sources and Disclaimer

- Caution should be taken in interpreting this data as there may be changes in the number of sentinel sites reporting to the Pacific Syndromic Surveillance System.
- The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States to Global Influenza Surveillance and Response System (GISRS)'s online platform RespiMart ([Integrated influenza and other respiratory viruses surveillance output](#)) and open data that Ministries of Health published on its website or shared with the WHO Regional Officer for the Western Pacific.

Reference links:

1. Australia, Department of Health and Aged Care. List of nationally notifiable diseases. Updated on 4 March 2024. Available from: <https://www.health.gov.au/topics/communicable-diseases/nationally-notifiable-diseases/list>
2. Australia, Department of Health and Aged Care. National Communicable Disease Surveillance Dashboard. Available from: <https://nindss.health.gov.au/pbi-dashboard/>
3. China, National Health Commission (NHC). National Health Office Medical Emergency Letter. Updated on 6 January 2023. Available from: <http://www.nhc.gov.cn/yljys/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml>
4. China, NHC. Joint Prevention and Control Mechanism Comprehensive Issue. Updated on 7 January 2023. Available from: <http://www.nhc.gov.cn/xcs/zhengcwj/202301/bdc1ff75feb94934ae1dade176d30936.shtml>
5. China, National Disease Control and Prevention Administration. List of Notifiable Infectious Diseases. Available from: <https://www.ndcpa.gov.cn/jbkzxx/c100041/common/list.html>
6. Hongkong SAR China, Centre for Health Protection (CHP), Communicable Disease Surveillance: Case definitions. Updated on 7 September 2023. Available from: https://cdis.chp.gov.hk/CDIS_CENO_ONLINE/disease.html
7. Indonesia Ministry of Health EWARS guidelines 2023. Available from: [BUKU PEDOMAN SKDR PP KLB 2023](#)
8. Circular Letter of the Director General of P2 Number SR.03.01/C/1422/2025 concerning Vigilance against Increase in COVID-19 Cases, 28 May 2025. Available from: [Emerging Infections](#).
9. Japan, Ministry of Health, Labour and Welfare (MHLW). Notification by Physicians and Veterinarians under the act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases, COVID-19. Available from: <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-shitei-01.html>
10. Japan, National Institute of Infectious Diseases (NIID). Weekly surveillance report of SARS-CoV-2. Available from: <https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/12015-covid19-surveillance-report.html>
11. Japan, Acute Respiratory Infection Surveillance Weekly Report: https://id-info.jihs.go.jp/surveillance/idss/content/teiten_ARI/index.html
12. Republic of Korea, Korea Disease Control and Prevention Agency (KDCA). Press release on de-escalation of COVID-19 alert level from 1 May 2024. Available from: <https://www.kdca.go.kr/board/board.es>
13. Korea Influenza Weekly Report, <https://www.kdca.go.kr/board/board.es?mid=a30504000000&bid=0033>
14. Republic of Korea, KDCA. Classification of Notifiable Diseases. Available from: <https://ncov.kdca.go.kr/pot/ii/sttyInftnsds/sttyInftnsds.do>
15. Malaysia, Ministry of Health Malaysia. COVID-19 Management Guidelines in Malaysia. Updated in February 2024. Available from: [KKM Guidelines | COVID-19 MALAYSIA \(moh.gov.my\)](#).
16. New Zealand, Health New Zealand (Te Whatu ora). Communicable Disease Control Manual, COVID-19. Updated in January 2024. Available from: <https://www.tewhatauora.govt.nz/for-the-health-sector/health-sector-guidance/communicable-disease-control-manual/covid-19/#case-definition>
17. [Decision 3985/QD-BYT 2023 guiding COVID19 surveillance and prevention \(thuvienphapluat.vn\)](#)
18. [Circular 54/2015/TT-BYT on the regime of information on reporting and declaration of the latest infectious diseases \(thuvienphapluat.vn\)](#)